The application of high-throughput screening of the small molecules and computational drug design can be beneficial in the selective targeting of Nrf2 mutant or disrupting the Nrf2 and KEAP1 complex in HCC. This evidence concerns the gene NFE2L2 and hepatocellular carcinoma.